Background. To overcome some of the limitations of conventional microbiologic techniques, polymerase chain reaction (PCR)-based assays are proposed as useful tools for the diagnosis of visceral leishmaniasis.
NOTE. Data are no. (%) of patients, unless otherwise indicated. Group A includes HIV-uninfected adults, group B includes HIV-infected adults, and group C includes HIV-uninfected children. BMA, bone marrow aspirate; NP, not performed; PB, peripheral blood.
VL is caused by the Leishmania donovani complex, which includes the following 3 species with partly overlapping geographical distribution: L. donovani (found in India and Africa), Leishmania infantum (found in the Mediterranean basin, the Middle East, and Asia), and Leishmania chagasi (found in South America), which is now considered to be identical to L. infantum [2] .
VL is characterized by prolonged fever, weight loss, progressive anemia or pancytopenia, and hypergammaglobulinemia. The diagnosis of VL is traditionally based on serologic testing results and the direct demonstration of Leishmania parasites by microscopic examination and in vitro isolation [3] . Accepted limits of Leishmania serologic testing are reduced sensitivity in patients with severe underlying immunosuppression, the absence of discriminating power between active or past infections, and, consequently, lack of value in monitoring the parasitological response to specific therapy. On the other hand, microscopic examination requires invasive procedures, such as spleen and bone marrow aspiration (BMA). Splenic aspirate cytologic testing has an excellent sensitivity (95%) but is associated with the risk of severe complications when performed by inexperienced health care workers. The sensitivity of microscopic examination of BMA samples varies among different studies from 60% to 85% [3] . Finally, in vitro parasite isolation still remains the reference method to unequivocally identify the parasite at the species level, but it is expensive, cumbersome, and generally unhelpful in clinical practice because of the long duration of time (days to weeks) required to obtain a definitive result.
In the past decade, PCR has been increasingly used to detect Leishmania DNA in clinical samples, such as BMA and peripheral blood (PB) samples, for the diagnosis of VL and for parasite species characterization. Several target sequences, such as ribosomal RNA (rRNA) genes, the mini-exon derived RNA gene, the kinetoplast minicircles, and repetitive nuclear DNA sequences, have been used in published PCR assays [4] [5] [6] [7] [8] [9] [10] [11] . In the present study, we performed a comparative analysis of microscopic, serologic, and PCR-based diagnostic methods for detection of Leishmania species in a consecutive series of 68 adult and pediatric cases of VL that were observed in both immunocompetent and immunocompromised Italian patients.
PATIENTS AND METHODS
An 8-year prospective study was performed in Milan (Lombardy region, northern Italy) and Palermo (Sicily region, southern Italy) from January 1997 through January 2005. Five hundred ninety-four consecutive patients living in the Mediterranean area in Italy who presented with clinical signs and symptoms compatible with VL were included in the study. All VL cases were confirmed by serologic testing, direct examination, and/or culture (at least 1 positive criteria was required for confirmation)
The majority of patients enrolled at the Department of Infectious and Tropical Diseases at the L. Sacco University Hospital of Milan were HIV-positive adults (447 patients; 83.5%), and the individuals who were observed at the Institute of Infectious Pathology and Virology at the G. di Cristina Hospital of Palermo were exclusively immunocompetent children (55 children). In addition, 254 control subjects were studied to assess the specificity of the PCR assay. These included 229 healthy blood donors who were recruited from the ImmuneHematology Department of L. Sacco Hospital and 25 patients with a confirmed diagnosis of imported malaria.
Molecular studies. Details of specimen collection, processing, DNA extraction, and qualitative and semiquantitative PCR amplification of a 359-base pair fragment of the small rRNA gene of Leishmania species are described elsewhere [4, 9]. Molecular identification of Old World Leishmania species was performed by restriction fragment-length polymorphism analysis of a PCR-amplified specific nuclear repetitive genomic sequence, exactly as described by Minodier et al. [12] . In vitro isolation. Leishmania cultures were performed by seeding BMA specimens in blood agar media (Evans modified, Tobie's medium, and/or Sloppy Evans medium). Positive culture results were further characterized by the electrophoretic analysis of 15 enzymatic loci, using the techniques and zymodeme nomenclature of the World Health Organization Collaborating Centre of Montpellier [13] .
Serologic testing. The serologic diagnosis was performed by indirect immunofluorescence antibody (the threshold titer for positivity was 1у40), using an in-house manufactured antigen preparation from the World Health Organization reference strain of L. infantum or a commercial kit (Leishmania spot IF; BioMèrieux). In particular, serologic testing of samples from all children was performed with the in-house preparation at the Laboratorio di Parassitologia at the Istituto Superiore di Sanità (Rome, Italy). All of the other samples were analyzed with the commercial kit.
Statistical analysis was performed using the Mann-Whitney U test. All P values р.05 were considered to be statistically significant. This study followed the appropriate Italian ethical requirements and was approved by the local ethical committees. The parents gave informed consent before the enrollment of their children in the study.
RESULTS
During the study, a total of 1678 samples (1483 PB samples and 195 BMA samples) obtained from 594 patients were processed for Leishmania DNA PCR at our laboratory, either for the primary diagnosis or the follow-up of VL.
Overall, 68 patients (11.4%) received a diagnosis of VL, including 11 HIV-uninfected adults (group A), 20 HIV-infected adults (group B), and 37 immunocompetent HIV-uninfected children (group C) (table 1). Preliminary results of examination of 10 HIV-positive patients and 10 immunocompetent children in this series have been previously reported [9, 14] . Among the 447 HIV-infected patients, 89 had atypical mycobacteriosis, 67 had disseminated and/or pulmonary tuberculosis, 49 had nonHodgkin lymphoma, 49 had bacterial sepsis, 31 had pneumocystosis, 27 had Kaposi sarcoma, 23 had disseminated cytomegalovirus disease, 76 had other infectious or neoplastic diseases, and 36 had an unidentified cause of fever. Among the HIV-uninfected adult patients, 23 had non-Hodgkin lymphoma, 12 had Hodgkin lymphoma, 8 had autoimmune diseases, 4 had acute leukemia, and 11 had an unidentified cause of fever. Among the remaining 18 pediatric patients, 13 had acute leukemia, 2 had infectious mononucleosis, and 3 had non-Hodgkin lymphoma.
A total of 536 PB samples and 74 BMA samples from patients with confirmed VL were available for investigation by PCR during the study period. Specimens were distributed as follows: 69 PB specimens (range, 2-16 specimens per patient) and 6 BMA specimens (range, 1-2 specimens per patient) for group A, 306 PB specimens (range, 1-101 specimens per patient) and 24 BMA specimens (range, 1-4 specimens per patient) for group B, and 159 PB specimens (range, 2-15 specimens per patient) and 44 BMA specimens (range, 1-3 specimens per patient) for group C. Overall, the sensitivity of PCR in the primary diagnosis of VL was 95.7% (for BMA specimens) and Proposed clinical algorithm for the use of PCR in the primary diagnosis of visceral leishmaniasis. Leishmania serologic testing in immunocompromised patients is generally of little value, especially if performed with commercial kits, and, therefore, should be used as initial screening only in immunocompetent patients. Leishmania PCR, when available, has been shown to be extremely sensitive and specific, and it should be used to confirm the primary diagnosis of VL. Bone marrow aspirate (BMA) samples should be obtained only when PCR of a peripheral blood (PB) sample is negative for VL, to definitively exclude VL or to make an alternative diagnosis.
98.5% (for PB specimens)
. In all of the cases, the diagnosis of VL was obtained from a single initial sample. On the other hand, the sensitivities of in vitro isolation, Leishmania serologic testing, and microscopic examination of BMA samples were 76.2%, 85.5%, and 90.2%, respectively (table 1). In all of the study groups, PCR of PB samples exhibited the highest sensitivity, ranging from 97.1% (in group C) to 100% (in groups A and B ). Leishmania DNA was not detected by PCR in any sample from a negative control subject (i.e., 229 blood donors and 25 patients with imported malaria); therefore, the specificity of the assay was assumed to be 100%.
At diagnosis of primary VL, the median Leishmania DNA burden was higher in BMA samples than in PB samples (P ! ). In more detail, HIV-uninfected adults exhibited a 2 log 10 .001 higher parasite load in BMA samples, compared with that in PB samples ( ), and HIV-infected adults had comparable P p .01 levels of Leishmania DNA in the 2 anatomical districts. In HIVnegative children, the median Leishmania DNA levels were 1 log 10 higher in BMA samples ( ). Finally , significantly P p .001 higher levels of parasitaemia were observed in adults than in children ( ). P ! .009 Fifty-four patients were prospectively monitored using semiquantitative PCR of PB samples during periods ranging from 1 to 84 months (median duration, 6 months). In particular, median periods of molecular monitoring were 3 months for patients in group A, 13 months for patients in group B, and 6 months for patients in group C.
Clinical and parasitologic relapses were detected in 13 of 54 individuals, including 11 adults with AIDS (55%) and 2 HIVuninfected children (5%;
). In particular, 4 subjects with P ! .001 HIV infection experienced multiple relapses (range, 2-6 relapses). No recrudescences of VL were observed in HIV-uninfected adult patients (group A).
Immunocompetent children and adults cleared Leishmania DNA from PB within a few days from the start of treatment (median duration, 9 and 12 days, respectively). By contrast, the duration of time to Leishmania PCR negativity following the first cycle of specific therapy was consistently longer in individuals coinfected with HIV (median duration, 17.5 days). In particular, 4 (23.5 %) of 17 HIV-infected patients had undetectable Leishmania DNA in PB within 8 days from the start of treatment; 5 of these patients cleared Leishmania DNA within 5 weeks, 4 patients cleared Leishmania DNA within 8 weeks, and the remaining 3 patients cleared Leishmania DNA within 21 weeks.
Results of Leishmania PCR of PB samples reverted to positive in 11 HIV-infected patients, 7 of whom thereafter had persistently positive results during the follow-up period (median du-ration, 21 months; range, 3-72 months). Six of these 7 patients experienced at least 1 relapse of VL during the follow-up period.
PCR and restriction fragment-length polymorphism analysis for Leishmania species identification was performed for all patients with the following results: 10 patients had L. infantum infection and 1 patient had L. donovani infection in group A, 16 patients had L. infantum infection and 4 patients had L. donovani infection in group B, and 37 patients had L. infantum infection in group C. One hundred percent perfect concordance was observed with the isoenzyme typing method in the 19 patients for whom the method was available (1 patient had L. infantum infection and 1 patient had L. donovani infection in group A, 2 patients had L. donovani infection in group B, and 15 patients had L. infantum infection in group C).
DISCUSSION
The application of PCR to detect parasite DNA for the diagnosis of cutaneous leishmaniasis and VL in tissues has been reported since the early 1990s [5, 10] . The use of PCR of PB samples to diagnose VL was first reported in 1995 by 4 investigators [15] [16] [17] [18] who employed this technique in patients with confirmed VL in India [15, 16] , Brazil, Kenya [16, 18] , and Switzerland (the patients in Switzerland had imported disease) [17] . Since then, at least 29 studies have been published with the description of different protocols that use, as the target of PCR amplification, either the Leishmania kinetoplast DNA minicircle, which is present at thousands of copies per parasite [16, 21, 23, 25-27, 29, 30, 31, 33, 34, 36, 37, 39, 41] , or the small subunit rRNA gene, which is repeated 1100 times in the Leishmania genome [6, 9, 14, 17, 20, 22, 24, 28, 32, 35, 38, 40] (table 2) .
In our study, we chose the small subunit rRNA gene of the parasite as the target sequence. The primers were those originally described by van Eys et al. [4] , which have been shown to specifically amplify all known human pathogenic Leishmania species.
When compared with serologic testing, in vitro culture, and direct bone marrow examination, the PCR performed on whole blood samples appeared, in our study, to be more sensitive, with an overall sensitivity of 98.5%, considering all categories of patients studied. Moreover, the PCR of PB samples performed slightly better than PCR of BMA samples with regard to sensitivity (98.5% vs. 95.7%). Our results are in good agreement with those reported by several investigators who studied different groups of French, Spanish, and Indian patients [7, 26, 28, 33, 39] . However, in some other studies, the sensitivity of PCR of PB samples was unsatisfactory, ranging from as low as 54% (in a small study performed with Chinese children [11] ) to 70%-85% [22-25, 37, 38, 40] . These discrepancies have been ascribed either to differences in the volume of blood tested in the PCR [22] , to differences in the timing of sample collection [6, 15, 22] , or to differences pertaining to the species of Leishmania parasites, some of which may indeed circulate less frequently or at lower levels in the infected host [22] . In addition, in a study by Singh et al. [23] , it was speculated that some patients with negative results of PCR of PB samples might have undergone a previous private treatment before admission to the hospital. Finally, in at least 2 studies, the use of blood samples spotted on filter paper might have negatively influenced the results [26, 39] .
It is also worth noting that the sensitivity of Leishmania PCR of PB samples was superior to all the conventional diagnostic techniques in HIV-infected and HIV-uninfected adults but was inferior to serologic testing in HIV-negative children (sensitivity of PCR of PB samples vs. sensitivity of serologic testing, 97.1% vs. 100%). A high sensitivity of Leishmania serologic testing was also recently reported by Cruz et al. [40] in a study involving 25 Spanish children. However, in the same study, the authors reported a lower sensitivity of Leishmania PCR of PB samples, compared with our present and past experience [14] .
The specificity of our PCR assay was also excellent (100%), because no false-positive result was obtained either in the negative control tubes or from negative control patients. Overall specificities of 100% were reported in 23 of 28 studies [7, 9, 11, 14-17, 20-23, 25, 27-30, 32, 34-37, 39, 40] , with the lowest values being those reported in the study by De Doncker et al. [38] . Of note, De Doncker et al. [38] found a 100% specificity using Belgian blood donors as negative controls, compared with 87.2% specificity when individuals living in an area where VL was endemic were used as negative controls.
It is generally accepted that, in patients with VL, the parasite load in PB samples is lower than that in BMA samples [7] . In addition, it is commonly believed that the parasite burden in immunocompetent patients is lower than that in patients with VL and concomitant HIV infection [32, 38] . However, these assumptions are thus far only speculative and, to our knowledge, have not been formally demonstrated. The hypothesis that higher levels of parasitaemia occur in HIV-infected patients was indirectly inferred by the observation that, in these patients, Leishmania parasites could be readily isolated from PB samples [41] . In our study, using semiquantitative PCR, we demonstrated that, if we considered all patients, irrespective of age and immune status, the median parasite DNA load detected in BMA samples was 10 times higher than that detected in PB samples. This is also confirmed by the analysis of HIV-uninfected children and adults. However, HIV-infected patients did not have statistically significant differences in parasite burden measured in simultaneously obtained PB and BMA samples. In addition, the parasite load detected in PB samples was significantly higher in HIV-infected patients than in HIV-uninfected children but was not significantly higher in HIV-infected patients than it was in HIV-uninfected adults.
With regard to the usefulness of PCR in the monitoring of patients undergoing specific treatment, to date, 13 studies have been published [7, 9, 14, 16, 22, 27, 28, 30, 32, 35, [39] [40] [41] , of which only 7 have specifically addressed the issue [7, 9, 14, 28, 30, 39, 41] (table 3) . Immunocompetent patients rapidly clear Leishmania DNA from peripheral blood [14, 16, 30, 39] , confirming a good concordance between clinical cure and PCR results. However, few possible exceptions to the rule have been reported [30, 39] .
On the other hand, patients with VL and concomitant HIV infection have a completely different course of Leishmania DNAemia while receiving specific therapy. Indeed, the majority of HIV-infected patients do not clear Leishmania DNA from PB [9, 27, 28, 32] or show a rapid reappearance of Leishmania DNA when specific therapy is interrupted. Both situations are generally-albeit, not invariably-associated with clinical relapse [28, 42] . It remains to be determined if it will be possible to define a cutoff value for Leishmania DNAemia that will allow researchers to predict the future development of clinical relapses of the disease in HIV-infected patients.
Isoenzyme analysis is currently considered to be the gold standard for the differentiation of Leishmania parasites at the species level, but this technique is laborious and time-consuming, is available only in a few laboratories, and, above all, requires prior isolation of the parasite. In our study, using a PCR and restriction fragment-length polymorphism protocol that was originally described by Minodier et al. [12] , we readily identified, at the species level, all 68 cases of VL. Interestingly, we identified 5 cases of VL in which L. donovani was implicated. The first case was observed in a immunocompetent Italian patient who had lived and traveled in India for 7 years, and the remaining 4 cases occurred in HIV-infected intravenous drug users. In 2 of the latter cases, no evidence of travel history to areas where L. donovani is endemic was found, which lends support to the hypothesis of the introduction of the parasite in parenteral drug users through the artificial epidemic cycle [43] . Finally, for the 19 cases for which standard isoenzyme characterization of Leishmania species was available, we found perfect concordance between the 2 techniques that we used. Thus, molecular characterization of Leishmania species may overcome the need for parasite isolation. However, it should be noted that the PCR and restriction fragment-length polymorphism protocol we used in our study is unable to discriminate, at the species level, Leishmania parasites of the New World belonging to Leishmania braziliensis (e.g., Leishmania braziliensis and Leishmania peruviana) and the Leishmania guyanensis complex (e.g., Leishmania guyanensis and Leishmania panamensis).
In summary, on the basis of the results of our study and of previous reports, we propose the algorithm reported in figure  1 for the primary diagnosis of VL in patients presenting with fever, hepatosplenomegaly, and pancytopenia. Because the diagnostic yield of PB appears to be at least equivalent to that of BMA when Leishmania PCR is used in both immunocompromised and immunocompetent patients, few justifications remain to perform first-line BMA in clinical practice when the diagnosis of VL is suspected.
